U.S., Nov. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07923877) titled 'Induction Chemoimmunotherapy to Prevent Laryngectomy in Advanced Laryngeal Cancer and Hypopharyngeal Cancer' on Oct. 29.
Brief Summary: This phase II trial tests the effect of early (induction) standard chemoimmunotherapy with carboplatin, paclitaxel and pembrolizumab in preventing more extensive surgery to remove the voice box (laryngectomy), in patients with laryngeal squamous cell cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or hypopharyngeal cancer of any stage. Carboplatin is in a class of medications known as platinum-containing compounds. It wor...